Claude Nicaise Sells 2,491 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Stock

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Director Claude Nicaise sold 2,491 shares of the firm’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the sale, the director now owns 27,812 shares of the company’s stock, valued at approximately $2,771,187.68. This represents a 8.22 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Sarepta Therapeutics Stock Performance

NASDAQ SRPT opened at $97.19 on Friday. The firm’s fifty day moving average price is $111.73 and its two-hundred day moving average price is $120.10. The stock has a market cap of $9.43 billion, a PE ratio of 77.75 and a beta of 0.79. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. Sarepta Therapeutics, Inc. has a fifty-two week low of $97.06 and a fifty-two week high of $173.25.

Hedge Funds Weigh In On Sarepta Therapeutics

A number of hedge funds have recently modified their holdings of the business. Charles Schwab Investment Management Inc. raised its holdings in Sarepta Therapeutics by 2.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 623,749 shares of the biotechnology company’s stock worth $75,842,000 after purchasing an additional 12,000 shares during the last quarter. Simplify Asset Management Inc. lifted its holdings in Sarepta Therapeutics by 84.6% in the third quarter. Simplify Asset Management Inc. now owns 193,010 shares of the biotechnology company’s stock valued at $24,105,000 after buying an additional 88,474 shares during the period. Geode Capital Management LLC grew its holdings in Sarepta Therapeutics by 2.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock worth $211,910,000 after acquiring an additional 44,306 shares during the period. Summit Partners Public Asset Management LLC raised its position in shares of Sarepta Therapeutics by 547.9% in the 3rd quarter. Summit Partners Public Asset Management LLC now owns 138,118 shares of the biotechnology company’s stock worth $17,250,000 after acquiring an additional 116,800 shares in the last quarter. Finally, Larson Financial Group LLC lifted its stake in shares of Sarepta Therapeutics by 1,649.8% in the 3rd quarter. Larson Financial Group LLC now owns 8,749 shares of the biotechnology company’s stock valued at $1,093,000 after purchasing an additional 8,249 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. StockNews.com cut Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. Piper Sandler lowered their price objective on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 27th. Deutsche Bank Aktiengesellschaft started coverage on shares of Sarepta Therapeutics in a research report on Tuesday, February 11th. They issued a “hold” rating and a $136.00 target price for the company. HC Wainwright reaffirmed a “sell” rating and set a $75.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, February 27th. Finally, Royal Bank of Canada cut their price objective on shares of Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating for the company in a report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Sarepta Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $170.41.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.